News

According to a new study, marital status and education level may impact treatment and overall outcomes for patients with mantle cell lymphoma.

Janssen Pharmaceutical Companies of Johnson & Johnson announced that they are not perusing the regulatory submission for apalutamide and abiraterone acetate as treatment of chemotherapy-naïve metastatic castration-resistant prostate cancer after the combination was not found to show significant benefit over the control combination of prednisone and abiraterone acetate.

The FDA has granted breakthrough therapy designation to bemarituzumab for the first-line treatment of patients with HER2-negative metastatic and locally advanced gastric and gastroesophageal adenocarcinoma who harbor FGFR2b overexpression or amplification.

William H. Bradley, MD discusses the 5-year follow-up of the ongoing SOLO-1 trial, which is determining the efficacy of maintenance olaparib in patients with BRCA1/2-mutated advanced ovarian cancer.

In an interview with Targeted Oncology, Katelyn Handley, MD, discussed two studies on ovarian cancer subtypes and the use of a frailty index to determine patient outcomes before, during, and after ovarian cancer debulking surgery.

The FDA has granted an orphan drug designation to CA-4948, a first-in-class, small-molecule inhibitor of IRAK4, for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.

The FDA has granted priority review for 2 supplemental biologics license applications for enfortumab vedotin-ejfv for the treatment of a subset of patients with locally advanced or metastatic urothelial cancer.

A new report on ibrutinib-resistant mantle cell lymphoma patient-derived xenograft mouse models shows the potential benefit of the EZH1/2 inhibitor OR-S1, as other similar inhibitors have shown benefit in patients with hematologic cancers.

Recent updates to the National Comprehensive Cancer Network’s guidelines for renal cell carcinoma reflect quick integration of new agents and combination regimens to provide patients with RCC with more treatment options and the most up-to-date options.

GlaxoSmithKline plc has announced that they will stop enrolling patients in the phase 2 INDUCE-3 and INDUCE-4 trials while simultaneously ending the use of feladilimab, originally GSK3359609, for the treatment of PD-L1-positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma after the recommendation of the Independent Data Monitoring Committee.

Darovasertib, a selective protein kinase C inhibitor, demonstrated promising response rates, survival, and reduction in tumor size as treatment of patients with metastatic uveal melanoma treatment both alone and in combination with binimetinib, according to preliminary results from a 7-armed phase 1/2 clinical trial.

The FDA has lifted a partial clinical hold on a phase 1 clinical trial of SBP-101 in combination with the standard-of-care agents gemcitabine and nab-paclitaxel as treatment of patients with metastatic pancreatic ductal adenocarcinoma.

The FDA has approved nivolumab in combination with certain chemotherapies for the initial treatment of advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

In patients with breast cancer, who were predominantly hormone receptor–positive, 37.8% had a conversion to HER2-positive status that led to significant benefit from frontline treatment with taxane-trastuzumab with or without pertuzumab.

Pirtobrutinib showed promising efficacy and safety as treatment of patients with mantle cell lymphoma, demonstrating the potential to serve an unmet medical need.

A phase 3 study with the goal of demonstrating overall survival benefit with imetelstat versus best available therapy in patients with refractory myelofibrosis has dosed the first patient with the experimental agent.

In an interview with Targeted Oncology, Srdan Verstovsek, MD, PhD, discussed the impact of ruxolitinib on MF and other issues facing the patient population. 

In phase 1b trial, treatment with tislelizumab in combination with sitravatinib achieved early antitumor activity and demonstrated a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.

The FDA has granted a rare pediatric disease designation to the novel p-STAT3 inhibitor WP1066 for the treatment of patients with the rare brain and spinal cord malignancy, ependymoma.

In patients with desmoid tumors, tegavivant has demonstrated early safety and tolerability.

The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin.

GTB-3550 TriKE had demonstrated early clinical promise as a monotherapy for the treatment of high-risk myelodysplastic syndromes and refractory/relapsed acute myeloid leukemia.

The FDA has authorized the marking of GI Genius, the first device that uses artificial intelligence to assist in the diagnosis of colon cancer.

An accelerated approval was granted by the FDA to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

The FDA has granted orphan drug designation to CYNK-001, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, for the treatment of patients with malignant gliomas.

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

A patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of tamoxifen, after a Safe to Proceed Letter was granted by the FDA, according to a press release by Atossa Therapeutics, Inc.

Gedatolisib, a first-in-class PI3K/mTOR inhibitor, plus palbociclib and endocrine therapy demonstrated tolerability and preliminary efficacy in patients with ER+/HER2- advanced or metastatic breast cancer.

In preclinical models of acute myeloid leukemia with FLT3 internal tandem duplication mutation, AMG 176 in combination with gilteritinib demonstrated the ability to synergistically target the disease.

After treatment with savolitinib, undetectability of MET Exon 14 in the circulating tumor DNA of patients with non‒small cell lung cancer was found to be associated with prolonged progression-free survival, and overall survival.